Most patients were men (61.9%), had an ECOG performance status of 0 (81.0%), had BRAF wild‐type disease (78.6%), had a normal level of lactate dehydrogenase (97.6%), and had received no prior systemic therapy for advanced melanoma (59.5%). This evidence concerns the gene BRAF and melanoma.